Volume 22: Issue 1 (Apr 2023): Disorders of Divalent Ions, Renal Bone Disease and Nephrolithiasis

Friedman PA: Mechanisms of renal calcium transport. Exp Nephrol 8: 343–350, 2000 10.1159/000020688 PubMed

Friedman PA: Mechanisms of renal calcium transport. Exp Nephrol 8: 343–350, 2000 10.1159/000020688 PubMed)| false
• Search Google Scholar
• Export Citation

Muto S, Hata M, Taniguchi J, Tsuruoka S, Moriwaki K, Saitou M, et al.: Claudin-2-deficient mice are defective in the leaky and cation-selective paracellular permeability properties of renal proximal tubules. Proc Natl Acad Sci USA 107: 8011–8016, 2010 10.1073/pnas.0912901107 PubMed

Muto S, Hata M, Taniguchi J, Tsuruoka S, Moriwaki K, Saitou M, et al.: Claudin-2-deficient mice are defective in the leaky and cation-selective paracellular permeability properties of renal proximal tubules. Proc Natl Acad Sci USA 107: 8011–8016, 2010 10.1073/pnas.0912901107 PubMed)| false
• Search Google Scholar
• Export Citation

Curry JN, Yu ASL: Paracellular calcium transport in the proximal tubule and the formation of kidney stones. Am J Physiol Renal Physiol 316: F966–F969, 2019 10.1152/ajprenal.00519.2018 PubMed

Curry JN, Yu ASL: Paracellular calcium transport in the proximal tubule and the formation of kidney stones. Am J Physiol Renal Physiol 316: F966–F969, 2019 10.1152/ajprenal.00519.2018 PubMed)| false
• Search Google Scholar
• Export Citation

Curry JN, Saurette M, Askari M, Pei L, Filla MB, Beggs MR, et al.: Claudin-2 deficiency associates with hypercalciuria in mice and human kidney stone disease. J Clin Invest 130: 1948–1960, 2020 10.1172/JCI127750 PubMed

Curry JN, Saurette M, Askari M, Pei L, Filla MB, Beggs MR, et al.: Claudin-2 deficiency associates with hypercalciuria in mice and human kidney stone disease. J Clin Invest 130: 1948–1960, 2020 10.1172/JCI127750 PubMed)| false
• Search Google Scholar
• Export Citation

Simon DB, Lu Y, Choate KA, Velazquez H, Al-Sabban E, Praga M, et al.: Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption. Science 285: 103–106, 1999 10.1126/science.285.5424.103 PubMed

Simon DB, Lu Y, Choate KA, Velazquez H, Al-Sabban E, Praga M, et al.: Paracellin-1, a renal tight junction protein required for paracellular Mg²⁺ resorption. Science 285: 103–106, 1999 10.1126/science.285.5424.103 PubMed)| false
• Search Google Scholar
• Export Citation

Konrad M, Schaller A, Seelow D, Pandey AV, Waldegger S, Lesslauer A, et al.: Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet 79: 949–957, 2006 10.1086/508617 PubMed

Konrad M, Schaller A, Seelow D, Pandey AV, Waldegger S, Lesslauer A, et al.: Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet 79: 949–957, 2006 10.1086/508617 PubMed)| false
• Search Google Scholar
• Export Citation

Gong Y, Renigunta V, Himmerkus N, Zhang J, Renigunta A, Bleich M, et al.: Claudin-14 regulates renal Ca++ transport in response to CaSR signalling via a novel microRNA pathway. EMBO J 31: 1999–2012, 2012 10.1038/emboj.2012.49 PubMed

Gong Y, Renigunta V, Himmerkus N, Zhang J, Renigunta A, Bleich M, et al.: Claudin-14 regulates renal Ca⁺⁺ transport in response to CaSR signalling via a novel microRNA pathway. EMBO J 31: 1999–2012, 2012 10.1038/emboj.2012.49 PubMed)| false
• Search Google Scholar
• Export Citation

Thorleifsson G, Holm H, Edvardsson V, Walters GB, Styrkarsdottir U, Gudbjartsson DF, et al.: Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet 41: 926–930, 2009 10.1038/ng.404 PubMed

Thorleifsson G, Holm H, Edvardsson V, Walters GB, Styrkarsdottir U, Gudbjartsson DF, et al.: Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet 41: 926–930, 2009 10.1038/ng.404 PubMed)| false
• Search Google Scholar
• Export Citation

Figueres L, Bruneau S, Prot-Bertoye C, Brideau G, Néel M, Griveau C, et al.: Hypomagnesemia, hypocalcemia, and tubulointerstitial nephropathy caused by claudin-16 autoantibodies. J Am Soc Nephrol 33: 1402–1410, 2022 10.1681/asn.2022010060 PubMed

Figueres L, Bruneau S, Prot-Bertoye C, Brideau G, Néel M, Griveau C, et al.: Hypomagnesemia, hypocalcemia, and tubulointerstitial nephropathy caused by claudin-16 autoantibodies. J Am Soc Nephrol 33: 1402–1410, 2022 10.1681/asn.2022010060 PubMed)| false
• Search Google Scholar
• Export Citation

Gong Y, Hou J: Claudins in barrier and transport function-the kidney. Pflugers Arch 469: 105–113, 2017 10.1007/s00424-016-1906-6 PubMed

Gong Y, Hou J: Claudins in barrier and transport function-the kidney. Pflugers Arch 469: 105–113, 2017 10.1007/s00424-016-1906-6 PubMed)| false
• Search Google Scholar
• Export Citation

Marneros AG: Magnesium and calcium homeostasis depend on KCTD1 function in the distal nephron. Cell Rep 34: 108616, 2021 10.1016/j.celrep.2020.108616 PubMed

Marneros AG: Magnesium and calcium homeostasis depend on KCTD1 function in the distal nephron. Cell Rep 34: 108616, 2021 10.1016/j.celrep.2020.108616 PubMed)| false
• Search Google Scholar
• Export Citation

Riccardi D, Valenti G: Localization and function of the renal calcium-sensing receptor. Nat Rev Nephrol 12: 414–425, 2016 10.1038/nrneph.2016.59 PubMed

Riccardi D, Valenti G: Localization and function of the renal calcium-sensing receptor. Nat Rev Nephrol 12: 414–425, 2016 10.1038/nrneph.2016.59 PubMed)| false
• Search Google Scholar
• Export Citation

Bazúa-Valenti S, Rojas-Vega L, Castañeda-Bueno M, Barrera-Chimal J, Bautista R, Cervantes-Pérez LG, et al.: The calcium-sensing receptor increases activity of the renal NCC through the WNK4-SPAK pathway. J Am Soc Nephrol 29: 1838–1848, 2018 10.1681/ASN.2017111155 PubMed

Bazúa-Valenti S, Rojas-Vega L, Castañeda-Bueno M, Barrera-Chimal J, Bautista R, Cervantes-Pérez LG, et al.: The calcium-sensing receptor increases activity of the renal NCC through the WNK4-SPAK pathway. J Am Soc Nephrol 29: 1838–1848, 2018 10.1681/ASN.2017111155 PubMed)| false
• Search Google Scholar
• Export Citation

van Megen WH, Tan RSG, Alexander RT, Dimke H: Differential parathyroid and kidney Ca2+-sensing receptor activation in autosomal dominant hypocalcemia 1. EBioMedicine 78: 103947, 2022 10.1016/j.ebiom.2022.103947 PubMed

van Megen WH, Tan RSG, Alexander RT, Dimke H: Differential parathyroid and kidney Ca²⁺-sensing receptor activation in autosomal dominant hypocalcemia 1. EBioMedicine 78: 103947, 2022 10.1016/j.ebiom.2022.103947 PubMed)| false
• Search Google Scholar
• Export Citation

Stevenson M, Pagnamenta AT, Mack HG, et al.: The Bartter-Gitelman spectrum: 50-year follow-up with revision of diagnosis after whole-genome sequencing. J Endocr Soc 6: bvac079, 2022 10.1210/jendso/bvac079PubMed

Stevenson M, Pagnamenta AT, Mack HG, et al.: The Bartter-Gitelman spectrum: 50-year follow-up with revision of diagnosis after whole-genome sequencing. J Endocr Soc 6: bvac079, 2022 10.1210/jendso/bvac079PubMed)| false
• Search Google Scholar
• Export Citation

Talmage RV, Matthews JL, Mobley HT, Lester GE: Calcium homeostasis and bone surface proteins, a postulated vital process for plasma calcium control. J Musculoskelet Neuronal Interact 3: 194–200, 2003 PubMed

Talmage RV, Matthews JL, Mobley HT, Lester GE: Calcium homeostasis and bone surface proteins, a postulated vital process for plasma calcium control. J Musculoskelet Neuronal Interact 3: 194–200, 2003 PubMed)| false
• Search Google Scholar
• Export Citation

Andrukhova O, Smorodchenko A, Egerbacher M, Streicher C, Zeitz U, Goetz R, et al.: FGF23 promotes renal calcium reabsorption through the TRPV5 channel. EMBO J 33: 229–246, 2014 10.1002/embj.201284188 PubMed

Andrukhova O, Smorodchenko A, Egerbacher M, Streicher C, Zeitz U, Goetz R, et al.: FGF23 promotes renal calcium reabsorption through the TRPV5 channel. EMBO J 33: 229–246, 2014 10.1002/embj.201284188 PubMed)| false
• Search Google Scholar
• Export Citation

Renkema KY, Nijenhuis T, van der Eerden BC, van der Kemp AW, Weinans H, van Leeuwen JP, et al.: Hypervitaminosis D mediates compensatory Ca2+ hyperabsorption in TRPV5 knockout mice. J Am Soc Nephrol 16: 3188–3195, 2005 10.1681/ASN.2005060632 PubMed

Renkema KY, Nijenhuis T, van der Eerden BC, van der Kemp AW, Weinans H, van Leeuwen JP, et al.: Hypervitaminosis D mediates compensatory Ca²⁺ hyperabsorption in TRPV5 knockout mice. J Am Soc Nephrol 16: 3188–3195, 2005 10.1681/ASN.2005060632 PubMed)| false
• Search Google Scholar
• Export Citation

Baron R, Kneissel M: WNT signaling in bone homeostasis and disease: From human mutations to treatments. Nat Med 19: 179–192, 2013 10.1038/nm.3074 PubMed

Baron R, Kneissel M: WNT signaling in bone homeostasis and disease: From human mutations to treatments. Nat Med 19: 179–192, 2013 10.1038/nm.3074 PubMed)| false
• Search Google Scholar
• Export Citation

Ryan ZC, Ketha H, McNulty MS, McGee-Lawrence M, Craig TA, Grande JP, et al.: Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci USA 110: 6199–6204, 2013 10.1073/pnas.1221255110 PubMed

Ryan ZC, Ketha H, McNulty MS, McGee-Lawrence M, Craig TA, Grande JP, et al.: Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium. Proc Natl Acad Sci USA 110: 6199–6204, 2013 10.1073/pnas.1221255110 PubMed)| false
• Search Google Scholar
• Export Citation

van der Wijst J, Tutakhel OAZ, Bos C, Danser AHJ, Hoorn EJ, Hoenderop JGJ, et al.: Effects of a high-sodium/low-potassium diet on renal calcium, magnesium, and phosphate handling. Am J Physiol Renal Physiol 315: F110–F122, 2018 10.1152/ajprenal.00379.2017 PubMed

van der Wijst J, Tutakhel OAZ, Bos C, Danser AHJ, Hoorn EJ, Hoenderop JGJ, et al.: Effects of a high-sodium/low-potassium diet on renal calcium, magnesium, and phosphate handling. Am J Physiol Renal Physiol 315: F110–F122, 2018 10.1152/ajprenal.00379.2017 PubMed)| false
• Search Google Scholar
• Export Citation

Bushinsky DA, Krieger NS: Effects of acid on bone. Kidney Int 101: 1160–1170, 2022 10.1016/j.kint.2022.02.032 PubMed

Bushinsky DA, Krieger NS: Effects of acid on bone. Kidney Int 101: 1160–1170, 2022 10.1016/j.kint.2022.02.032 PubMed)| false
• Search Google Scholar
• Export Citation

Imenez Silva PH, Katamesh-Benabbas C, Chan K, Pastor Arroyo EM, Knöpfel T, Bettoni C, et al.: The proton-activated ovarian cancer G protein-coupled receptor 1 (OGR1) is responsible for renal calcium loss during acidosis. Kidney Int 97: 920–933, 2020 10.1016/j.kint.2019.12.006 PubMed

Imenez Silva PH, Katamesh-Benabbas C, Chan K, Pastor Arroyo EM, Knöpfel T, Bettoni C, et al.: The proton-activated ovarian cancer G protein-coupled receptor 1 (OGR1) is responsible for renal calcium loss during acidosis. Kidney Int 97: 920–933, 2020 10.1016/j.kint.2019.12.006 PubMed)| false
• Search Google Scholar
• Export Citation

Khalil R, Kim NR, Jardi F, Vanderschueren D, Claessens F, Decallonne B: Sex steroids and the kidney: Role in renal calcium and phosphate handling. Mol Cell Endocrinol 465: 61–72, 2018 10.1016/j.mce.2017.11.011 PubMed

Khalil R, Kim NR, Jardi F, Vanderschueren D, Claessens F, Decallonne B: Sex steroids and the kidney: Role in renal calcium and phosphate handling. Mol Cell Endocrinol 465: 61–72, 2018 10.1016/j.mce.2017.11.011 PubMed)| false
• Search Google Scholar
• Export Citation

Hsu YJ, Dimke H, Schoeber JP, Hsu SC, Lin SH, Chu P, et al.: Testosterone increases urinary calcium excretion and inhibits expression of renal calcium transport proteins. Kidney Int 77: 601–608, 2010 10.1038/ki.2009.522 PubMed

Hsu YJ, Dimke H, Schoeber JP, Hsu SC, Lin SH, Chu P, et al.: Testosterone increases urinary calcium excretion and inhibits expression of renal calcium transport proteins. Kidney Int 77: 601–608, 2010 10.1038/ki.2009.522 PubMed)| false
• Search Google Scholar
• Export Citation

Lin PH, Jian CY, Chou JC, Chen CW, Chen CC, Soong C, et al.: Induction of renal senescence marker protein-30 (SMP30) expression by testosterone and its contribution to urinary calcium absorption in male rats. Sci Rep 6: 32085, 2016 10.1038/srep32085 PubMed

Lin PH, Jian CY, Chou JC, Chen CW, Chen CC, Soong C, et al.: Induction of renal senescence marker protein-30 (SMP30) expression by testosterone and its contribution to urinary calcium absorption in male rats. Sci Rep 6: 32085, 2016 10.1038/srep32085 PubMed)| false
• Search Google Scholar
• Export Citation

Beggs MR, Appel I, Svenningsen P, Skjødt K, Alexander RT, Dimke H: Expression of transcellular and paracellular calcium and magnesium transport proteins in renal and intestinal epithelia during lactation. Am J Physiol Renal Physiol 313: F629–F640, 2017 10.1152/ajprenal.00680.2016 PubMed

Beggs MR, Appel I, Svenningsen P, Skjødt K, Alexander RT, Dimke H: Expression of transcellular and paracellular calcium and magnesium transport proteins in renal and intestinal epithelia during lactation. Am J Physiol Renal Physiol 313: F629–F640, 2017 10.1152/ajprenal.00680.2016 PubMed)| false
• Search Google Scholar
• Export Citation

Rutkowski JM, Pastor J, Sun K, Park SK, Bobulescu IA, Chen CT, et al.: Adiponectin alters renal calcium and phosphate excretion through regulation of klotho expression. Kidney Int 91: 324–337, 2017 10.1016/j.kint.2016.09.016 PubMed

Rutkowski JM, Pastor J, Sun K, Park SK, Bobulescu IA, Chen CT, et al.: Adiponectin alters renal calcium and phosphate excretion through regulation of klotho expression. Kidney Int 91: 324–337, 2017 10.1016/j.kint.2016.09.016 PubMed)| false
• Search Google Scholar
• Export Citation

Vall-Palomar M, Madariaga L, Ariceta G: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol 36: 3045–3055, 2021 10.1007/s00467-021-04968-2 PubMed

Vall-Palomar M, Madariaga L, Ariceta G: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol 36: 3045–3055, 2021 10.1007/s00467-021-04968-2 PubMed)| false
• Search Google Scholar
• Export Citation

Vall-Palomar M, Burballa C, Claverie-Martín F, Meseguer A, Ariceta G: Heterogeneity is a common ground in familial hypomagnesemia with hypercalciuria and nephrocalcinosis caused by CLDN19 gene mutations. J Nephrol 34: 2053–2062, 2021 10.1007/s40620-021-01054-6 PubMed

Vall-Palomar M, Burballa C, Claverie-Martín F, Meseguer A, Ariceta G: Heterogeneity is a common ground in familial hypomagnesemia with hypercalciuria and nephrocalcinosis caused by CLDN19 gene mutations. J Nephrol 34: 2053–2062, 2021 10.1007/s40620-021-01054-6 PubMed)| false
• Search Google Scholar
• Export Citation

Hou J, Renigunta V, Nie M, Sunq A, Himmerkus N, Quintanova C, et al.: Phosphorylated claudin-16 interacts with Trpv5 and regulates transcellular calcium transport in the kidney. Proc Natl Acad Sci USA 116: 19176–19186, 2019 10.1073/pnas.1902042116 PubMed

Hou J, Renigunta V, Nie M, Sunq A, Himmerkus N, Quintanova C, et al.: Phosphorylated claudin-16 interacts with Trpv5 and regulates transcellular calcium transport in the kidney. Proc Natl Acad Sci USA 116: 19176–19186, 2019 10.1073/pnas.1902042116 PubMed)| false
• Search Google Scholar
• Export Citation

Kang TS, Siegel LM: Congenital macular scars in siblings from CLDN19 mutations. J AAPOS 25: 316–318, 2021 10.1016/j.jaapos.2021.05.008 PubMed

Kang TS, Siegel LM: Congenital macular scars in siblings from CLDN19 mutations. J AAPOS 25: 316–318, 2021 10.1016/j.jaapos.2021.05.008 PubMed)| false
• Search Google Scholar
• Export Citation

Eckardt KU, Alper SL, Antignac C, Bleyer AJ, Chauveau D, Dahan K, et al; Kidney Disease: Improving Global Outcomes: Autosomal dominant tubulointerstitial kidney disease: Diagnosis, classification, and management: A KDIGO consensus report. Kidney Int 88: 676–683, 2015 10.1038/ki.2015.28 PubMed

Eckardt KU, Alper SL, Antignac C, Bleyer AJ, Chauveau D, Dahan K, et al; Kidney Disease: Improving Global Outcomes: Autosomal dominant tubulointerstitial kidney disease: Diagnosis, classification, and management: A KDIGO consensus report. Kidney Int 88: 676–683, 2015 10.1038/ki.2015.28 PubMed)| false
• Search Google Scholar
• Export Citation

Kompatscher A, de Baaij JHF, Aboudehen K, Farahani S, van Son LHJ, Milatz S, et al.: Transcription factor HNF1β regulates expression of the calcium-sensing receptor in the thick ascending limb of the kidney. Am J Physiol Renal Physiol 315: F27–F35, 2018 10.1152/ajprenal.00601.2017 PubMed

Kompatscher A, de Baaij JHF, Aboudehen K, Farahani S, van Son LHJ, Milatz S, et al.: Transcription factor HNF1β regulates expression of the calcium-sensing receptor in the thick ascending limb of the kidney. Am J Physiol Renal Physiol 315: F27–F35, 2018 10.1152/ajprenal.00601.2017 PubMed)| false
• Search Google Scholar
• Export Citation

Sicking M, Živná M, Bhadra P, Barešová V, Tirincsi A, Hadzibeganovic D, et al.: Phenylbutyrate rescues the transport defect of the Sec61α mutations V67G and T185A for renin. Life Sci Alliance 5: e202101150, 2022 10.26508/lsa.202101150 PubMed

Sicking M, Živná M, Bhadra P, Barešová V, Tirincsi A, Hadzibeganovic D, et al.: Phenylbutyrate rescues the transport defect of the Sec61α mutations V67G and T185A for renin. Life Sci Alliance 5: e202101150, 2022 10.26508/lsa.202101150 PubMed)| false
• Search Google Scholar
• Export Citation

Wu M, Feng Y, Ye GX, Han YC, Wang SS, Ni HF, et al.: Calcium-sensing receptor activation attenuates collagen expression in renal proximal tubular epithelial cells. Am J Physiol Renal Physiol 316: F1006–F1015, 2019 10.1152/ajprenal.00413.2018 PubMed

Wu M, Feng Y, Ye GX, Han YC, Wang SS, Ni HF, et al.: Calcium-sensing receptor activation attenuates collagen expression in renal proximal tubular epithelial cells. Am J Physiol Renal Physiol 316: F1006–F1015, 2019 10.1152/ajprenal.00413.2018 PubMed)| false
• Search Google Scholar
• Export Citation

Mai X, Shang J, Liang S, Yu B, Yuan J, Lin Y, et al.: Blockade of orai1 store-operated calcium entry protects against renal fibrosis. J Am Soc Nephrol 27: 3063–3078, 2016 10.1681/ASN.2015080889 PubMed

Mai X, Shang J, Liang S, Yu B, Yuan J, Lin Y, et al.: Blockade of orai1 store-operated calcium entry protects against renal fibrosis. J Am Soc Nephrol 27: 3063–3078, 2016 10.1681/ASN.2015080889 PubMed)| false
• Search Google Scholar
• Export Citation

Hering L, Rahman M, Hoch H, Markó L, Yang G, Reil A, et al.: α2A-adrenoceptors modulate renal sympathetic neurotransmission and protect against hypertensive kidney disease. J Am Soc Nephrol 31: 783–798, 2020 10.1681/ASN.2019060599 PubMed

Hering L, Rahman M, Hoch H, Markó L, Yang G, Reil A, et al.: α2A-adrenoceptors modulate renal sympathetic neurotransmission and protect against hypertensive kidney disease. J Am Soc Nephrol 31: 783–798, 2020 10.1681/ASN.2019060599 PubMed)| false
• Search Google Scholar
• Export Citation

Mishima K, Nakasatomi M, Takahashi S, Ikeuchi H, Sakairi T, Kaneko Y, et al.: Attenuation of renal fibrosis after unilateral ureteral obstruction in mice lacking the N-type calcium channel. PLoS One 14: e0223496, 2019 10.1371/journal.pone.0223496 PubMed

Mishima K, Nakasatomi M, Takahashi S, Ikeuchi H, Sakairi T, Kaneko Y, et al.: Attenuation of renal fibrosis after unilateral ureteral obstruction in mice lacking the N-type calcium channel. PLoS One 14: e0223496, 2019 10.1371/journal.pone.0223496 PubMed)| false
• Search Google Scholar
• Export Citation

Zhao X, Kong Y, Liang B, Xu J, Lin Y, Zhou N, et al.: Mechanosensitive Piezo1 channels mediate renal fibrosis. JCI Insight 7: e152330, 2022 10.1172/jci.insight.152330 PubMed

Zhao X, Kong Y, Liang B, Xu J, Lin Y, Zhou N, et al.: Mechanosensitive Piezo1 channels mediate renal fibrosis. JCI Insight 7: e152330, 2022 10.1172/jci.insight.152330 PubMed)| false
• Search Google Scholar
• Export Citation

Liu X, Tang J, Chen XZ: Role of PKD2 in the endoplasmic reticulum calcium homeostasis. Front Physiol 13: 962571, 2022 10.3389/fphys.2022.962571 PubMed

Liu X, Tang J, Chen XZ: Role of PKD2 in the endoplasmic reticulum calcium homeostasis. Front Physiol 13: 962571, 2022 10.3389/fphys.2022.962571 PubMed)| false
• Search Google Scholar
• Export Citation

Di Mise A, Tamma G, Ranieri M, Centrone M, van den Heuvel L, Mekahli D, et al.: Activation of calcium-sensing receptor increases intracellular calcium and decreases cAMP and mTOR in PKD1 deficient cells. Sci Rep 8: 5704, 2018 10.1038/s41598-018-23732-5 PubMed

Di Mise A, Tamma G, Ranieri M, Centrone M, van den Heuvel L, Mekahli D, et al.: Activation of calcium-sensing receptor increases intracellular calcium and decreases cAMP and mTOR in PKD1 deficient cells. Sci Rep 8: 5704, 2018 10.1038/s41598-018-23732-5 PubMed)| false
• Search Google Scholar
• Export Citation

Di Mise A, Ranieri M, Centrone M, Venneri M, Tamma G, Valenti D, et al.: Activation of the calcium-sensing receptor corrects the impaired mitochondrial energy status observed in renal polycystin-1 knockdown cells modeling autosomal dominant polycystic kidney disease. Front Mol Biosci 5: 77, 2018 10.3389/fmolb.2018.00077 PubMed

Di Mise A, Ranieri M, Centrone M, Venneri M, Tamma G, Valenti D, et al.: Activation of the calcium-sensing receptor corrects the impaired mitochondrial energy status observed in renal polycystin-1 knockdown cells modeling autosomal dominant polycystic kidney disease. Front Mol Biosci 5: 77, 2018 10.3389/fmolb.2018.00077 PubMed)| false
• Search Google Scholar
• Export Citation

Li Z, Zhou J, Li Y, Yang F, Lian X, Liu W: Mitochondrial TRPC3 promotes cell proliferation by regulating the mitochondrial calcium and metabolism in renal polycystin-2 knockdown cells. Int Urol Nephrol 51: 1059–1070, 2019 10.1007/s11255-019-02149-7 PubMed

Li Z, Zhou J, Li Y, Yang F, Lian X, Liu W: Mitochondrial TRPC3 promotes cell proliferation by regulating the mitochondrial calcium and metabolism in renal polycystin-2 knockdown cells. Int Urol Nephrol 51: 1059–1070, 2019 10.1007/s11255-019-02149-7 PubMed)| false
• Search Google Scholar
• Export Citation

Di Mise A, Wang X, Ye H, Pellegrini L, Torres VE, Valenti G: Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease. FASEB J 35: e21874, 2021 10.1096/fj.202100774R PubMed

Di Mise A, Wang X, Ye H, Pellegrini L, Torres VE, Valenti G: Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease. FASEB J 35: e21874, 2021 10.1096/fj.202100774R PubMed)| false
• Search Google Scholar
• Export Citation

Ning B, Guo C, Kong A, Li K, Xie Y, Shi H, et al.: Calcium signaling mediates cell death and crosstalk with autophagy in kidney disease. Cells 10: 3204, 2021 10.3390/cells10113204 PubMed

Ning B, Guo C, Kong A, Li K, Xie Y, Shi H, et al.: Calcium signaling mediates cell death and crosstalk with autophagy in kidney disease. Cells 10: 3204, 2021 10.3390/cells10113204 PubMed)| false
• Search Google Scholar
• Export Citation

Ilatovskaya DV, Blass G, Palygin O, Levchenko V, Pavlov TS, Grzybowski MN, et al.: A NOX4/TRPC6 pathway in podocyte calcium regulation and renal damage in diabetic kidney disease. J Am Soc Nephrol 29: 1917–1927, 2018 10.1681/ASN.2018030280 PubMed

Ilatovskaya DV, Blass G, Palygin O, Levchenko V, Pavlov TS, Grzybowski MN, et al.: A NOX4/TRPC6 pathway in podocyte calcium regulation and renal damage in diabetic kidney disease. J Am Soc Nephrol 29: 1917–1927, 2018 10.1681/ASN.2018030280 PubMed)| false
• Search Google Scholar
• Export Citation

Palygin O, Klemens CA, Isaeva E, Levchenko V, Spires DR, Dissanayake LV, et al.: Characterization of purinergic receptor 2 signaling in podocytes from diabetic kidneys. iScience 24: 102528, 2021 10.1016/j.isci.2021.102528 PubMed

Palygin O, Klemens CA, Isaeva E, Levchenko V, Spires DR, Dissanayake LV, et al.: Characterization of purinergic receptor 2 signaling in podocytes from diabetic kidneys. iScience 24: 102528, 2021 10.1016/j.isci.2021.102528 PubMed)| false
• Search Google Scholar
• Export Citation

Vasco RFV, Takayama L, Pereira RMR, Moyses RMA, Elias RM: Effects of diuretics furosemide and hydrochlorothiazide on CKD-MBD: A prospective randomized study. Bone Rep 14: 100746, 2021 10.1016/j.bonr.2021.100746 PubMed

Vasco RFV, Takayama L, Pereira RMR, Moyses RMA, Elias RM: Effects of diuretics furosemide and hydrochlorothiazide on CKD-MBD: A prospective randomized study. Bone Rep 14: 100746, 2021 10.1016/j.bonr.2021.100746 PubMed)| false
• Search Google Scholar
• Export Citation

Shroff R, Lalayiannis AD, Fewtrell M, Schmitt CP, Bayazit A, Askiti V, et al.: Naturally occurring stable calcium isotope ratios are a novel biomarker of bone calcium balance in chronic kidney disease. Kidney Int 102: 613–623, 2022 10.1016/j.kint.2022.04.024 PubMed

Shroff R, Lalayiannis AD, Fewtrell M, Schmitt CP, Bayazit A, Askiti V, et al.: Naturally occurring stable calcium isotope ratios are a novel biomarker of bone calcium balance in chronic kidney disease. Kidney Int 102: 613–623, 2022 10.1016/j.kint.2022.04.024 PubMed)| false
• Search Google Scholar
• Export Citation

Das S, Clézardin P, Kamel S, Brazier M, Mentaverri R: The CaSR in pathogenesis of breast cancer: A new target for early stage bone metastases. Front Oncol 10: 69, 2020 10.3389/fonc.2020.00069 PubMed

Das S, Clézardin P, Kamel S, Brazier M, Mentaverri R: The CaSR in pathogenesis of breast cancer: A new target for early stage bone metastases. Front Oncol 10: 69, 2020 10.3389/fonc.2020.00069 PubMed)| false
• Search Google Scholar
• Export Citation

Jeong S, Kim JH, Kim MG, Han N, Kim IW, Kim T, et al.: Genetic polymorphisms of CASR and cancer risk: Evidence from meta-analysis and HuGE review. OncoTargets Ther 9: 655–669, 2016 10.2147/ott.S97602 PubMed

Jeong S, Kim JH, Kim MG, Han N, Kim IW, Kim T, et al.: Genetic polymorphisms of CASR and cancer risk: Evidence from meta-analysis and HuGE review. OncoTargets Ther 9: 655–669, 2016 10.2147/ott.S97602 PubMed)| false
• Search Google Scholar
• Export Citation

Orduña-Castillo LB, Del-Río-Robles JE, García-Jiménez I, Zavala-Barrera C, Beltrán-Navarro YM, Hidalgo-Moyle JJ, et al.: Calcium sensing receptor stimulates breast cancer cell migration via the Gβγ-AKT-mTORC2 signaling pathway. J Cell Commun Signal 16: 239–252, 2022 10.1007/s12079-021-00662-y PubMed

Orduña-Castillo LB, Del-Río-Robles JE, García-Jiménez I, Zavala-Barrera C, Beltrán-Navarro YM, Hidalgo-Moyle JJ, et al.: Calcium sensing receptor stimulates breast cancer cell migration via the Gβγ-AKT-mTORC2 signaling pathway. J Cell Commun Signal 16: 239–252, 2022 10.1007/s12079-021-00662-y PubMed)| false
• Search Google Scholar
• Export Citation

Frees S, Breuksch I, Haber T, Bauer HK, Chavez-Munoz C, Raven P, et al.: Calcium-sensing receptor (CaSR) promotes development of bone metastasis in renal cell carcinoma. Oncotarget 9: 15766–15779, 2018 10.18632/oncotarget.24607 PubMed

Frees S, Breuksch I, Haber T, Bauer HK, Chavez-Munoz C, Raven P, et al.: Calcium-sensing receptor (CaSR) promotes development of bone metastasis in renal cell carcinoma. Oncotarget 9: 15766–15779, 2018 10.18632/oncotarget.24607 PubMed)| false
• Search Google Scholar
• Export Citation

Rosner MH: Hypocalcemia in a patient with cancer. Clin J Am Soc Nephrol 12: 696–699, 2017 10.2215/cjn.13241216 PubMed

Rosner MH: Hypocalcemia in a patient with cancer. Clin J Am Soc Nephrol 12: 696–699, 2017 10.2215/cjn.13241216 PubMed)| false
• Search Google Scholar
• Export Citation

Miyaoka D, Imanishi Y, Ohara M, Hayashi N, Nagata Y, Yamada S, et al.: Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency. Osteoporos Int 30: 241–249, 2019 10.1007/s00198-018-4688-1 PubMed

Miyaoka D, Imanishi Y, Ohara M, Hayashi N, Nagata Y, Yamada S, et al.: Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency. Osteoporos Int 30: 241–249, 2019 10.1007/s00198-018-4688-1 PubMed)| false
• Search Google Scholar
• Export Citation

Broadwell A, Chines A, Ebeling PR, Franek E, Huang S, Smith S, et al.: Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab 106: 397–409, 2021 10.1210/clinem/dgaa851 PubMed

Broadwell A, Chines A, Ebeling PR, Franek E, Huang S, Smith S, et al.: Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab 106: 397–409, 2021 10.1210/clinem/dgaa851 PubMed)| false
• Search Google Scholar
• Export Citation

Hiramatsu R, Ubara Y, Sawa N, Sakai A: Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: A 2-year observational study. Nephrol Dial Transplant 36: 1900–1907, 2021 10.1093/ndt/gfaa359 PubMed

Hiramatsu R, Ubara Y, Sawa N, Sakai A: Hypocalcemia and bone mineral changes in hemodialysis patients with low bone mass treated with denosumab: A 2-year observational study. Nephrol Dial Transplant 36: 1900–1907, 2021 10.1093/ndt/gfaa359 PubMed)| false
• Search Google Scholar
• Export Citation

Thongprayoon C, Acharya P, Acharya C, Chenbhanich J, Bathini T, Boonpheng B, et al.: Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: A meta-analysis of observational studies. Osteoporos Int 29: 1737–1745, 2018 10.1007/s00198-018-4533-6 PubMed

Thongprayoon C, Acharya P, Acharya C, Chenbhanich J, Bathini T, Boonpheng B, et al.: Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: A meta-analysis of observational studies. Osteoporos Int 29: 1737–1745, 2018 10.1007/s00198-018-4533-6 PubMed)| false
• Search Google Scholar
• Export Citation

Thongprayoon C, Acharya P, Aeddula NR, Torres-Ortiz A, Bathini T, Sharma K, et al.: Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: A systematic review and meta-analysis. Arch Osteoporos 14: 35, 2019 10.1007/s11657-019-0587-0 PubMed

Thongprayoon C, Acharya P, Aeddula NR, Torres-Ortiz A, Bathini T, Sharma K, et al.: Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: A systematic review and meta-analysis. Arch Osteoporos 14: 35, 2019 10.1007/s11657-019-0587-0 PubMed)| false
• Search Google Scholar
• Export Citation

Nanmoku K, Shinzato T, Kubo T, Shimizu T, Yagisawa T: Effects of denosumab on hypercalcemia and bone mineral density loss in kidney transplant recipients. Clin Nephrol 92: 1–8, 2019 10.5414/CN109723 PubMed

Nanmoku K, Shinzato T, Kubo T, Shimizu T, Yagisawa T: Effects of denosumab on hypercalcemia and bone mineral density loss in kidney transplant recipients. Clin Nephrol 92: 1–8, 2019 10.5414/CN109723 PubMed)| false
• Search Google Scholar
• Export Citation

Kanbayashi Y, Sakaguchi K, Hongo F, Ishikawa T, Tabuchi Y, Ukimura O, et al.: Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis. Sci Rep 11: 978, 2021 10.1038/s41598-020-80243-y PubMed

Kanbayashi Y, Sakaguchi K, Hongo F, Ishikawa T, Tabuchi Y, Ukimura O, et al.: Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis. Sci Rep 11: 978, 2021 10.1038/s41598-020-80243-y PubMed)| false
• Search Google Scholar
• Export Citation

Manohar S, Kompotiatis P, Thongprayoon C, Cheungpasitporn W, Herrmann J, Herrmann SM: Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: Meta-analysis. Nephrol Dial Transplant 34: 108–117, 2019 10.1093/ndt/gfy105 PubMed

Manohar S, Kompotiatis P, Thongprayoon C, Cheungpasitporn W, Herrmann J, Herrmann SM: Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: Meta-analysis. Nephrol Dial Transplant 34: 108–117, 2019 10.1093/ndt/gfy105 PubMed)| false
• Search Google Scholar
• Export Citation

Uppal NN, Workeneh BT, Rondon-Berrios H, Jhaveri KD: Electrolyte and acid-base disorders associated with cancer immunotherapy. Clin J Am Soc Nephrol 17: 922–933, 2022 10.2215/cjn.14671121 PubMed

Uppal NN, Workeneh BT, Rondon-Berrios H, Jhaveri KD: Electrolyte and acid-base disorders associated with cancer immunotherapy. Clin J Am Soc Nephrol 17: 922–933, 2022 10.2215/cjn.14671121 PubMed)| false
• Search Google Scholar
• Export Citation

Nalluru SS, Piranavan P, Ning Y, Ackula H, Siddiqui AD, Trivedi N: Hypocalcemia with immune checkpoint inhibitors: The disparity among various reports. Int J Endocrinol 2020: 7459268, 2020 10.1155/2020/7459268 PubMed

Nalluru SS, Piranavan P, Ning Y, Ackula H, Siddiqui AD, Trivedi N: Hypocalcemia with immune checkpoint inhibitors: The disparity among various reports. Int J Endocrinol 2020: 7459268, 2020 10.1155/2020/7459268 PubMed)| false
• Search Google Scholar
• Export Citation

Yu ST, Ge JN, Luo JY, Wei ZG, Sun BH, Lei ST: Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: A systematic review and meta-analysis. Cancer Manag Res 11: 1525–1532, 2019 10.2147/cmar.S191499 PubMed

Yu ST, Ge JN, Luo JY, Wei ZG, Sun BH, Lei ST: Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: A systematic review and meta-analysis. Cancer Manag Res 11: 1525–1532, 2019 10.2147/cmar.S191499 PubMed)| false
• Search Google Scholar
• Export Citation

Berends AMA, van der Horst-Schrivers ANA, Oosting SF, Kapiteijn EW, de Groot JWB, Links TP: Hypocalcemia induced by tyrosine kinase inhibitors: Targeted treatment with ‘untargeted’ side effects. Acta Oncol 59: 726–729, 2020 10.1080/0284186x.2020.1726455 PubMed

Berends AMA, van der Horst-Schrivers ANA, Oosting SF, Kapiteijn EW, de Groot JWB, Links TP: Hypocalcemia induced by tyrosine kinase inhibitors: Targeted treatment with ‘untargeted’ side effects. Acta Oncol 59: 726–729, 2020 10.1080/0284186x.2020.1726455 PubMed)| false
• Search Google Scholar
• Export Citation

Ho LY, Wong PN, Sin HK, Wong YY, Lo KC, Chan SF, et al.: Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism. BMC Nephrol 18: 12, 2017 10.1186/s12882-016-0421-5 PubMed

Ho LY, Wong PN, Sin HK, Wong YY, Lo KC, Chan SF, et al.: Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism. BMC Nephrol 18: 12, 2017 10.1186/s12882-016-0421-5 PubMed)| false
• Search Google Scholar
• Export Citation

Ge Y, Yang G, Wang N, Zha X, Yu X, Mao H, et al.: Bone metabolism markers and hungry bone syndrome after parathyroidectomy in dialysis patients with secondary hyperparathyroidism. Int Urol Nephrol 51: 1443–1449, 2019 10.1007/s11255-019-02217-y PubMed

Ge Y, Yang G, Wang N, Zha X, Yu X, Mao H, et al.: Bone metabolism markers and hungry bone syndrome after parathyroidectomy in dialysis patients with secondary hyperparathyroidism. Int Urol Nephrol 51: 1443–1449, 2019 10.1007/s11255-019-02217-y PubMed)| false
• Search Google Scholar
• Export Citation

Jain N, Reilly RF: Hungry bone syndrome. Curr Opin Nephrol Hypertens 26: 250–255, 2017 10.1097/MNH.0000000000000327 PubMed

Jain N, Reilly RF: Hungry bone syndrome. Curr Opin Nephrol Hypertens 26: 250–255, 2017 10.1097/MNH.0000000000000327 PubMed)| false
• Search Google Scholar
• Export Citation

Gao D, Lou Y, Cui Y, Liu S, Cui W, Sun G: Risk factors for hypocalcemia in dialysis patients with refractory secondary hyperparathyroidism after parathyroidectomy: A meta-analysis. Ren Fail 44: 503–512, 2022 10.1080/0886022x.2022.2048856 PubMed

Gao D, Lou Y, Cui Y, Liu S, Cui W, Sun G: Risk factors for hypocalcemia in dialysis patients with refractory secondary hyperparathyroidism after parathyroidectomy: A meta-analysis. Ren Fail 44: 503–512, 2022 10.1080/0886022x.2022.2048856 PubMed)| false
• Search Google Scholar
• Export Citation

Zhao S, Gan W, Xie W, Cao J, Zhang L, Wen P, et al.: A single-center experience of parathyroidectomy in 1500 cases for secondary hyperparathyroidism: A retrospective study. Ren Fail 44: 23–29, 2022 10.1080/0886022x.2021.2016445 PubMed

Zhao S, Gan W, Xie W, Cao J, Zhang L, Wen P, et al.: A single-center experience of parathyroidectomy in 1500 cases for secondary hyperparathyroidism: A retrospective study. Ren Fail 44: 23–29, 2022 10.1080/0886022x.2021.2016445 PubMed)| false
• Search Google Scholar
• Export Citation

Sun Y, Tian B, Sheng Z, Wan P, Xu T, Yao L: Efficacy and safety of cinacalcet compared with other treatments for secondary hyperparathyroidism in patients with chronic kidney disease or end-stage renal disease: A meta-analysis. BMC Nephrol 21: 316, 2020 10.1186/s12882-019-1639-9 PubMed

Sun Y, Tian B, Sheng Z, Wan P, Xu T, Yao L: Efficacy and safety of cinacalcet compared with other treatments for secondary hyperparathyroidism in patients with chronic kidney disease or end-stage renal disease: A meta-analysis. BMC Nephrol 21: 316, 2020 10.1186/s12882-019-1639-9 PubMed)| false
• Search Google Scholar
• Export Citation

Bernardor J, Flammier S, Salles JP, Amouroux C, Castanet M, Lienhardt A, et al.: Off-label use of cinacalcet in pediatric primary hyperparathyroidism: A French multicenter experience. Front Pediatr 10: 926986, 2022 10.3389/fped.2022.926986 PubMed

Bernardor J, Flammier S, Salles JP, Amouroux C, Castanet M, Lienhardt A, et al.: Off-label use of cinacalcet in pediatric primary hyperparathyroidism: A French multicenter experience. Front Pediatr 10: 926986, 2022 10.3389/fped.2022.926986 PubMed)| false
• Search Google Scholar
• Export Citation

Sheerah AA, Al-Ahmed RA, El-Desoky SM, Alhasan KA, Albanna AS, Shalaby MA, et al.: Cinacalcet for severe secondary hyperparathyroidism in children with end-stage kidney disease. Saudi J Kidney Dis Transpl 32: 1628–1636, 2021 10.4103/1319-2442.352423 PubMed

Sheerah AA, Al-Ahmed RA, El-Desoky SM, Alhasan KA, Albanna AS, Shalaby MA, et al.: Cinacalcet for severe secondary hyperparathyroidism in children with end-stage kidney disease. Saudi J Kidney Dis Transpl 32: 1628–1636, 2021 10.4103/1319-2442.352423 PubMed)| false
• Search Google Scholar
• Export Citation

Wang AX, Liu S, Montez-Rath ME, Chertow GM, Lenihan CR: Parathyroidectomy and cinacalcet use in medicare-insured kidney transplant recipients. Am J Kidney Dis 81: 270–280.e1, 2023 10.1053/j.ajkd.2022.07.015 PubMed

Wang AX, Liu S, Montez-Rath ME, Chertow GM, Lenihan CR: Parathyroidectomy and cinacalcet use in medicare-insured kidney transplant recipients. Am J Kidney Dis 81: 270–280.e1, 2023 10.1053/j.ajkd.2022.07.015 PubMed)| false
• Search Google Scholar
• Export Citation

Floege J, Tsirtsonis K, Iles J, Drueke TB, Chertow GM, Parfrey P: Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. Kidney Int 93: 1475–1482, 2018 10.1016/j.kint.2017.12.014 PubMed

Floege J, Tsirtsonis K, Iles J, Drueke TB, Chertow GM, Parfrey P: Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. Kidney Int 93: 1475–1482, 2018 10.1016/j.kint.2017.12.014 PubMed)| false
• Search Google Scholar
• Export Citation

Palmer SC, Mavridis D, Johnson DW, Tonelli M, Ruospo M, Strippoli GFM: Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: A systematic review and network meta-analysis. Am J Kidney Dis 76: 321–330, 2020 10.1053/j.ajkd.2020.02.439 PubMed

Palmer SC, Mavridis D, Johnson DW, Tonelli M, Ruospo M, Strippoli GFM: Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: A systematic review and network meta-analysis. Am J Kidney Dis 76: 321–330, 2020 10.1053/j.ajkd.2020.02.439 PubMed)| false
• Search Google Scholar
• Export Citation

Louie KS, Erhard C, Wheeler DC, Stenvinkel P, Fouqueray B, Floege J: Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: Predictors, therapeutic approaches and outcomes. J Nephrol 33: 803–816, 2020 10.1007/s40620-019-00686-z PubMed

Louie KS, Erhard C, Wheeler DC, Stenvinkel P, Fouqueray B, Floege J: Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: Predictors, therapeutic approaches and outcomes. J Nephrol 33: 803–816, 2020 10.1007/s40620-019-00686-z PubMed)| false
• Search Google Scholar
• Export Citation